Annals of Diagnostic Pathology
Volume 11, Issue 4 , Pages 235-240 , August 2007

Immunohistochemical detection of X-linked inhibitor of apoptosis (XIAP) in neoplastic and other thyroid disorders

  • Guang-Qian Xiao, MD, PhD

      Affiliations

    • Department of Pathology, Mount Sinai School of Medicine, New York, NY 10029, USA
    • ,
  • Pamela D. Unger, MD

      Affiliations

    • Department of Pathology, Mount Sinai School of Medicine, New York, NY 10029, USA
    • ,
  • David E. Burstein, MD

      Affiliations

    • Department of Pathology, Mount Sinai School of Medicine, New York, NY 10029, USA
    • Department of Oncologic Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 212 241 0364; fax: +1 212 534 7491.

References 

  1. Suzuki Y, Nakabayashi Y, Nakata K, et al. X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and -7 in distinct modes. J Biol Chem. 2001;276:27058–27063
  2. Yang YL, Li XM. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res. 2000;10:169–177
  3. Amantana A, London CA, Iversen PL, et al. X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther. 2004;3:699–707
  4. Bilim V, Kasahara T, Hara N, et al. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer. 2003;103:29–37
  5. Endo T, Abe S, Seidlar HB, et al. Expression of IAP family proteins in colon cancers from patients with different age groups. Cancer Immunol Immunother. 2004;53:770–776
  6. Li J, Sasaki H, Sheng YL, et al. Apoptosis and chemoresistance in human ovarian cancer: is Xiap a determinant?. Biol Signals Recept. 2000;9:122–130
  7. Nemoto T, Kitagawa M, Hasegawa M, et al. Expression of IAP family proteins in esophageal cancer. Exp Mol Pathol. 2004;76:253–259
  8. Ramp U, Krieg T, Caliskan E, et al. XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol. 2004;35:1022–1028
  9. Schultz IJ, Kiemeney LA, Witjes JA, et al. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res. 2003;23:3327–3331
  10. Shiraki K, Sugimoto K, Yamanaka Y, et al. Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma. Int J Mol Med. 2003;12:705–708
  11. Cao C, Mu Y, Hallahan DE, et al. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene. 2004;23:7047–7052
  12. Roa WH, Chen H, Fulton D, et al. X-linked inhibitor regulating TRAIL-induced apoptosis in chemoresistant human primary glioblastoma cells. Clin Invest Med. 2003;26:231–242
  13. Tamm I, Richter S, Scholz F, et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol J. 2004;5:489–495
  14. Muris JJ, Cillessen SA, Vos W, et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood. 2005;105:2916–2923
  15. Ekedahl J, Joseph B, Grigoriev MY, et al. Expression of inhibitor of apoptosis proteins in small- and non–small-cell lung carcinoma cells. Exp Cell Res. 2002;279:277–290
  16. Liu SS, Tsang BK, Cheung AN, et al. Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. Eur J Cancer. 2001;37:1104–1110
  17. Rutherford T, O'Malley D, Makkenchery A, et al. Phenoxodiol phase Ib/II study in patients with recurrent ovarian cancer that are resistant to second-line chemotherapy [abstr]. Proc Am Assoc Cancer Res. 2004;95:A4457
  18. Sapi E, Alvero AB, Chen W, et al. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol Res. 2004;14:567–578
  19. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003;22:6455–6457
  20. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol. 2002;13:3–16
  21. Cheung CC, Boerner SL, MacMillan CM, et al. Hyalinizing trabecular tumor of the thyroid: a variant of papillary carcinoma proved by molecular genetics. Am J Surg Pathol. 2000;24:1622–1626
  22. Schlumberger MJ. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest. 1999;22(Suppl):3–7
  23. Burstein DE, Nagi C, Wang BY, et al. Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and Hashimoto's thyroiditis: a stem cell hypothesis of papillary carcinoma oncogenesis. Hum Pathol. 2004;35:465–473
  24. Sheils O, Smyth P, Finn S, et al. RET/PTC rearrangements in Hashimoto's thyroiditis. Int J Surg Pathol. 2002;10:167–168
  25. Arif S, Blanes A, Diaz-Cano SJ. Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma. Histopathology. 2002;41:357–362
  26. Arscott PL, Stokes T, Myc A, et al. Fas (CD95) expression is up-regulated on papillary thyroid carcinoma. J Clin Endocrinol Metab. 1999;84:4246–4252
  27. Di Pasquale M, Rothstein JL, Palazzo JP. Pathologic features of Hashimoto's-associated papillary thyroid carcinomas. Hum Pathol. 2001;32:24–30
  28. Holcik M, Yeh C, Korneluk RG, et al. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene. 2000;19:4174–4177
  29. Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis. 2001;6:253–261
  30. Bannerji R, Kitada S, Flinn IW, et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol. 2003;21:1466–1471
  31. Ahmad M, Shi Y. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention. Oncogene. 2000;19:3363–3371
  32. Bhojani MS, Rossu BD, Rehemtulla A. TRAIL and anti-tumor responses. Cancer Biol Ther. 2003;2(Suppl 1):S71–S78
  33. de Matos PS, Ferreira AP, de Oliveira Facuri F, et al. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology. 2005;47:391–401
  34. Weber KB, Shroyer KR, Heinz DE, et al. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol. 2004;122:524–531
  35. Carcangiu ML, Zampi G, Rosai J. Poorly differentiated (insular) thyroid carcinoma. A reinterpretation of Langhans “wuchernde struma”. Am J Surg Pathol. 1984;8:655–668
  36. Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid. 1998;8:715–726

PII: S1092-9134(06)00082-7

doi: 10.1016/j.anndiagpath.2006.06.010

Annals of Diagnostic Pathology
Volume 11, Issue 4 , Pages 235-240 , August 2007

Article Tools

* Image Usage & Resolution